MDxHealth SA Logo

MDxHealth SA

ISIN

BE0003844611

Ticker

MDXH

Sector

Health Care

Sub-Industry

Biotechnology

Country

Belgium

Year Founded

2003

About MDxHealth SA

Company Description

Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of prostate cancer and other urologic diseases. The Company’s tests are based on proprietary genetic, epigenetic and other complex molecular technologies.

Mdxhealth is dedicated to providing highly accurate and clinically actionable urologic solutions to inform patient diagnosis and treatment while improving healthcare economics for payers and providers.

Served Area

Worldwide

Headquarters

CAP Business Center Rue d'Abhooz 31
4040, Herstal, Liège
Belgium

Financial statements

Download as Excel
Line item in (usd) 02.01.2020 01.01.2021 02.01.2021 01.01.2022 01.01.2023
Assets N/A 31,856,000.00 N/A 75,072,000.00 119,135,000.00
Noncurrent Assets N/A 8,765,000.00 N/A 8,466,000.00 89,986,000.00
Property Plant And Equipment N/A 973,000.00 N/A 1,671,000.00 3,791,000.00
Goodwill N/A N/A N/A 0.00 35,926,000.00
Intangible Assets Other Than Goodwill N/A 5,058,000.00 N/A 3,448,000.00 46,166,000.00
Current Assets N/A 23,091,000.00 N/A 66,606,000.00 29,149,000.00
Cash and cash equivalents 22,050,000.00 15,953,000.00 15,953,000.00 58,498,000.00 15,503,000.00
Other Current Assets N/A 1,043,000.00 N/A 1,615,000.00 1,962,000.00
Equity And Liabilities N/A 31,856,000.00 N/A 75,072,000.00 119,135,000.00
Equity 19,724,000.00 5,849,000.00 5,849,000.00 46,899,000.00 9,315,000.00
Issued Capital N/A 76,716,000.00 N/A 128,454,000.00 133,454,000.00
Retained Earnings N/A -215,300,000.00 N/A -244,302,000.00 -288,346,000.00
Share Premium N/A 136,349,000.00 N/A 153,177,000.00 153,177,000.00
Reserve Of Sharebased Payments N/A 9,385,000.00 N/A 10,607,000.00 11,474,000.00
Liabilities N/A 26,007,000.00 N/A 28,173,000.00 109,820,000.00
Noncurrent Liabilities N/A 12,986,000.00 N/A 11,741,000.00 91,542,000.00
Other Noncurrent Financial Liabilities N/A 690,000.00 N/A 1,466,000.00 53,537,000.00
Longterm Borrowings N/A 10,279,000.00 N/A 7,651,000.00 34,914,000.00
Current Liabilities N/A 13,021,000.00 N/A 16,432,000.00 18,278,000.00
Other Current Financial Liabilities N/A 909,000.00 N/A 961,000.00 2,327,000.00
Other Current Liabilities N/A 3,217,000.00 N/A 2,735,000.00 3,985,000.00
Line item in (usd) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 18,460,000.00 22,239,000.00 37,054,000.00
Revenue From Rendering Of Services 18,064,000.00 21,937,000.00 36,965,000.00
Revenue From Royalties 146,000.00 52,000.00 64,000.00
Licence Fee Income 250,000.00 250,000.00 25,000.00
Profit Loss From Operating Activities -27,123,000.00 -26,841,000.00 -37,900,000.00
Finance Income 4,000.00 11,000.00 N/A
Finance Costs 1,543,000.00 2,161,000.00 6,144,000.00
Profit Loss Before Tax -28,662,000.00 -29,002,000.00 -44,044,000.00
Income Tax Expense Continuing Operations 0.00 0.00 0.00
Profit (loss) -28,662,000.00 -29,002,000.00 -44,044,000.00
Line item in (usd) 01.01.2021 02.01.2020 01.01.2022 02.01.2021 01.01.2023
Profit (loss) -28,662,000.00 N/A -29,002,000.00 N/A -44,044,000.00
Adjustments For Decrease Increase In Inventories -1,132,000.00 N/A 413,000.00 N/A -416,000.00
Adjustments For Depreciation And Amortisation Expense 3,332,000.00 N/A 3,036,000.00 N/A 4,909,000.00
Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss 273,000.00 N/A 0.00 N/A 44,000.00
Adjustments For Sharebased Payments 1,295,000.00 N/A 1,222,000.00 N/A 867,000.00
Other Adjustments For Noncash Items 26,000.00 N/A -325,000.00 N/A -473,000.00
Cash Flows From Used In Operating Activities -20,244,000.00 N/A -22,548,000.00 N/A -34,118,000.00
Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities N/A N/A 0.00 N/A 25,000,000.00
Purchase Of Property Plant And Equipment Classified As Investing Activities 537,000.00 N/A 896,000.00 N/A 2,789,000.00
Purchase Of Intangible Assets Classified As Investing Activities N/A N/A 0.00 N/A 1,374,000.00
Interest Received Classified As Investing Activities 0.00 N/A 11,000.00 N/A N/A
Cash Flows From Used In Investing Activities -537,000.00 N/A -896,000.00 N/A -29,163,000.00
Proceeds From Issuing Shares 13,875,000.00 N/A 68,566,000.00 N/A 0.00
Proceeds From Borrowings Classified As Financing Activities 2,316,000.00 N/A 0.00 N/A 34,291,000.00
Repayments Of Borrowings Classified As Financing Activities N/A N/A 0.00 N/A 10,805,000.00
Payments Of Lease Liabilities Classified As Financing Activities 831,000.00 N/A 1,057,000.00 N/A 1,358,000.00
Interest Paid Classified As Financing Activities 1,070,000.00 N/A 1,011,000.00 N/A 1,412,000.00
Cash Flows From Used In Financing Activities 14,290,000.00 N/A 66,509,000.00 N/A 20,841,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes -6,491,000.00 N/A 43,065,000.00 N/A -42,440,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents 394,000.00 N/A -520,000.00 N/A -555,000.00
Cash and cash equivalents 15,953,000.00 22,050,000.00 58,498,000.00 15,953,000.00 15,503,000.00

Please note that some sums might not add up.

Filings & Publications

  • Consolidated Report 2021 - Q4 English 🇬🇧
  • Consolidated Report 2021 - Q4 French 🇫🇷

Insider Trades

Date Trading entity / Person Association Trade type Volume
11.09.2023 KALFUS RON Executive member Buy EUR 116,000.00
10.09.2023 Sollee Joseph Executive member Buy EUR 58,000.00
26.09.2022 KALFUS RON Executive member Buy EUR 136,800.00
23.09.2022 Sollee Joseph Executive member Buy EUR 136,800.00
26.01.2021 SLAGMULDER REGINE Board Buy EUR 79,653.00
25.01.2021 SLAGMULDER REGINE Board Buy EUR 216,298.00
21.09.2020 SLAGMULDER REGINE Board Buy EUR 37,824.80
18.09.2020 SLAGMULDER REGINE Board Buy EUR 7,223.00
17.09.2020 SLAGMULDER REGINE Board Buy EUR 2,860.40
16.09.2020 SLAGMULDER REGINE Board Buy EUR 4,988.20

Capital Markets Information

ISIN

BE0003844611

LEI

549300J3MG9F9B5FY646

Sub-Industry

Biotechnology

Listed Stock Exchange

Euronext Brussels

Contact Investor Relations Department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.